BWA
CLDX icon

Basecamp Wealth Advisors’s Celldex Therapeutics CLDX Stock Holding History

Basecamp Wealth Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$893 Hold
24
– – ﹤0.01% 1538
2026
Q1 		$761 Hold
24
– – ﹤0.01% 1625
2025
Q4 		$652 Buy
+24
New +$632 ﹤0.01% 1583

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Basecamp Wealth Advisors's CLDX Position: Q2 2026 in Review

Basecamp Wealth Advisors held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 24 shares worth $893. The position accounts for ﹤0.01% of the portfolio, ranked #1538.

Basecamp Wealth Advisors first reported a position in CLDX in Q4 2025 and has held it in 3 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Basecamp Wealth Advisors held 24 shares of Celldex Therapeutics worth $893 as of Q2 2026.
  • Basecamp Wealth Advisors left its Celldex Therapeutics share count unchanged in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1538 holding.
  • Basecamp Wealth Advisors first reported a position in Celldex Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.